Algeta announces that Xofigo® (radium-223 dichloride) has been approved by the US FDA Oslo, Norway, 15 May 2013 - Algeta ASA (OSE: ALGETA) announces that the US Food and Drug Administration (FDA) has approved Xofigo® (radium-223 dichloride) injection for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. Xofigo is the first alpha particle-emitting radioactive therapeutic agent approved by the FDA, that has demonstrated improvement in overall survival (OS) and delay in time to first symptomatic skeletal event (SSE) compared to placebo, as shown in the pivotal phase III ALSYMPCA trial. Read more
Originally only a small team, Algeta remains true to its heritage while steadily expanding into a global oncology company.
Read more
The Algeta Annual Report 2012 is now live! Find out more about the company’s progress over the past 12 months.
To the Annual Report
Algeta recognises that its corporate potential will only be fulfilled through collaborations.
Read moreAlgeta’s 1Q 2013 financial results are available
Algeta presented its First Quarter results on 15 May 2013, and the associated webcast can be accessed below.
The Algeta share is listed on the Oslo Stock Exchange under the ticker code ALGETA. All shares are freely transferable.
Algeta annually reviews the principles of corporate governance and how they are being implemented in the Group.
You are now leaving www.algeta.com. Links to sites outside of Algeta are provided as a resource to the viewer. Algeta accepts no responsibility for the content of linked sites.